Peptides, Policy, and PBMs: 2026 Quarter 3 Pharmacy Update with Annie West and Dae Lee
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Peptides, Policy, and PBMs: 2026 Quarter 3 Pharmacy Update with Annie West and Dae Lee
-
ナレーター：
-
著者：
Send us Fan Mail
Schedule an Rx Assessment
A LOT has happened recently in the Peptide market, but what exactly is new with peptides, the FDA, and the future of independent pharmacy?
On this episode of the Bottom Line Pharmacy Podcast, we're joined for our typical quarterly pharmacy update with @atrium24 . Annie West, Clinical Pharmacy Director and Dae Lee, PBM & Pharmacy Practice Group Board Co-Chair at Buchanan, Ingersoll & Rooney, P.C. to break down:
- The two-day PCAC meeting and the committee's recommendation
- What happens next in the FDA rulemaking process
- The dangerous peptide gray market
- The latest on PBM policy
And more!
Stay connected with Atrium24 and Dae Lee:
Dae Lee LinkedIn
Atrium24 Website
Atrium24 LinkedIn
Atrium24 Instagram
Atrium24 Facebook
Stay connected with us:
Facebook
Scotty Sykes – CPA, CFP LinkedIn
Scotty Sykes – CPA, CFP Twitter
Bonnie Bond – CPA LinkedIn
Bonnie Bond – CPA Twitter
More resources on this topic:
Podcast - Inside a Pharmacy AI Bot: Automating Independent Pharmacy
Podcast – Driving Independent Pharmacy Profitability in 2026 with Nicolette Mathey, PharmD, CEO of Atrium24
Podcast – 2026 Quarter 2 Pharmacy Update
Podcast – R&D Tax Credit, Trump Accounts, Taylor Swift's Wedding